The General Anesthesia Drugs market is estimated to be valued at US$ 4.95 Bn in 2023 and is expected to exhibit a CAGR of 4.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
General anesthesia drugs are used during surgical procedures to induce unconsciousness, muscle relaxation, and amnesia. They are administered by an anesthesiologist to ensure comfort and immobility in patients undergoing surgery or another medical procedure. Some common general anesthesia drugs include propofol, sevofluorane, desflurane, and dexmedetomidine. They find wide application in general surgery, gynecology, urology, orthopedics, and other fields.
Market Dynamics:
The General Anesthesia Drugs market is driven by the increasing number of surgical procedures performed worldwide. According to the National Health Service (NHS) of the UK, over 4.1 million surgical procedures were performed in England in 2020-2021. Rising cases of chronic diseases, accidents, and the growing geriatric population are contributing to the increasing demand for surgeries. Furthermore, technological advancements in anesthetic equipment and techniques are enabling anesthesia providers to custom-tailor anesthetic drugs and regimens to individual patient characteristics, which is expected to foster the popularity of general anesthesia. The market is also witnessing increasing demand for short-acting drugs to reduce patient recovery time in ambulatory settings. However, risks and complications associated with general anesthesia such as nausea, vomiting, respiratory depression and allergic reactions pose a challenge to market growth.
SWOT Analysis
Strength: General anesthesia drugs ensure efficient and safe surgical procedures. They provide complete unconsciousness and pain relief during surgery. Drugs like propofol are easy to administer and control. Diversity in products enables catering to individual patient needs.
Weakness: Side effects of anesthetic drugs can be life-threatening in some cases. Drugs require careful dosage and administration to avoid adverse reactions. Storage and handling of certain intravenous anesthetics need specialized facilities and trained staff.
Opportunity: Rise in number of surgical procedures due to growing geriatric population and chronic diseases. Increasing demand for ambulatory surgical centers drives the market. Growing healthcare expenditure in developing nations boosts the adoption of advanced anesthesia procedures.
Threats: Stringent regulations for drug approvals delay market entry of new drugs. Risk of drug shortage and supply chain disruptions hampers market growth. Threat of substitutes like regional anesthesia limits market potential.
Key Takeaways
The Global General Anesthesia Drugs Market Size is expected to witness high growth, exhibiting a CAGR of 4.1% over the forecast period, due to increasing number of surgical procedures worldwide.
Regional analysis
North America dominated the global market in 2023 and is projected to maintain its lead over 2023-2030. This is attributed to growing geriatric population and technological advancements in surgical techniques in the region. Asia Pacific is anticipated to grow at the fastest pace during the forecast period owing to improving healthcare infrastructure and rise in medical tourism in developing countries like China and India.
Key players
Key players operating in the general anesthesia drugs market are Baxter Healthcare, Dr. Reddy's Laboratories, Novartis International AG, Hospira, Maruishi, Hengrui, Lunan, Fresenius Kabi, Pfizer Inc., Hikma Pharmaceuticals, Sagent Pharmaceuticals, Teva Pharmaceuticals, Par Pharmaceutical, Viatris Inc., AbbVie, Piramal Critical Care, Aspen Global Incorporated, B. Braun SE, Abbott and Cosmo pharmaceuticals.
Read Our More Blogs : https://www.pressreleasebulletin.com/general-anesthesia-drugs-market-analysis-growth-forecast-outlook-2023-2030/
Sign in to leave a comment.